Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy

Safieh Ebrahimi; Elnaz Ghorbani; Majid Khazaei; Amir Avan; Mikhail Ryzhikov; Kayhan Azadmanesh; Seyed Mahdi Hassanian

doi:10.1002/jcb.25917

Interferon-Mediated Tumor Resistance to Oncolytic Virotherapy

J Cell Biochem. 2017 Aug;118(8):1994-1999. doi: 10.1002/jcb.25917. Epub 2017 Apr 25.

Authors

Safieh Ebrahimi¹, Elnaz Ghorbani², Majid Khazaei³, Amir Avan^{4

5}, Mikhail Ryzhikov⁶, Kayhan Azadmanesh⁷, Seyed Mahdi Hassanian^{1

4

8}

Affiliations

¹ Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
² Department of Microbiology, Al-Zahra University, Tehran, Iran.
³ Department of Medical Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁴ Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁵ Molecular Medicine Group, Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Department of Molecular Microbiology and Immunology, St. Louis University School of Medicine, Saint Louis, Missouri.
⁷ Virology Department, Pasteur Institute of Iran, Tehran, Iran.
⁸ Microanatomy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

PMID: 28135008
DOI: 10.1002/jcb.25917

Abstract

Interferons (INFs) elicit antiviral responses in tumor cells upon binding to cell surface receptors. Oncolytic virotherapy (OV) is an effective antitumor therapeutic approach which in combination with standard radiotherapy or chemotherapy regimens potentiates treatment responses in cancer patients. However, oncolytic viruses are susceptible to the IFN-induced antiviral state in the tumor microenvironment. A number of studies have, therefore, investigated the effects of combined therapy of IFN signaling pharmacological inhibitors with oncolytic viruses, which result in improved virus replication and oncolysis. This review summarizes the current knowledge of the mechanisms of interferon-mediated tumor resistance to oncolytic virotherapy and provides new insights regarding the effectiveness of combinatorial treatment strategies to attenuate INF-induced OV resistance for greater clinical significance in the treatment of cancer patients. J. Cell. Biochem. 118: 1994-1999, 2017. © 2017 Wiley Periodicals, Inc.

Keywords: CANCER; INTERFERON; ONCOLYTIC VIROTHERAPY.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Bone Marrow / immunology
Bone Marrow / pathology
Chemokine CXCL12 / genetics
Chemokine CXCL12 / immunology
Dinoprostone / immunology
Dinoprostone / metabolism
Extracellular Matrix / genetics
Extracellular Matrix / immunology
Extracellular Matrix / pathology
Extracellular Matrix Proteins / genetics
Extracellular Matrix Proteins / immunology
Gene Expression Regulation, Neoplastic / genetics
Gene Expression Regulation, Neoplastic / immunology*
Hematopoietic Stem Cells / immunology*
Hematopoietic Stem Cells / pathology
Humans
Integrins / genetics
Integrins / immunology
Interferons / genetics
Interferons / immunology*
Neoplasms / genetics
Neoplasms / immunology*
Neoplasms / pathology
Neoplasms / therapy
Oncolytic Virotherapy*
Oncolytic Viruses / growth & development
Oncolytic Viruses / immunology
Receptors, CXCR4 / genetics
Receptors, CXCR4 / immunology
Signal Transduction
Stem Cell Niche / genetics
Stem Cell Niche / immunology*

Substances

CXCL12 protein, human
CXCR4 protein, human
Chemokine CXCL12
Extracellular Matrix Proteins
Integrins
Receptors, CXCR4
Interferons
Dinoprostone